Tags : SARS-CoV-2


Qiagen’s PCR Tests Demonstrate Effectiveness in Detecting Mutations in SARS-CoV-2

Shots: Qiagen’s QIAstat-Dx and NeuMoDx tests remain accurate & effective in detecting SARS-CoV-2 infections The company started cross-checking variants in May’2020 & assessed the tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases. Qiagen will continue to conduct assessments on a biweekly basis Variants with potentially increased transmissibility include […]Read More

Clinical Trials

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Shots: The company presents the ongoing program of SARS-CoV-2 mutation surveillance for STI-2020 currently in pre/ clinical development for COVID-19 The data provides evidence of maintained binding potency in in vitro assays including the Spike amino acid changes found in SARS-CoV-2 viruses of the B.1.1.7 lineage, identified in the UK Additional neutralizing Abs were identified […]Read More


ViewPoints Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein

In a recent interview with PharmaShots Daniel-Adriano Silva, PhD, Co-founder and Vice President Head of Research at Neoleukin shared the significance and promise of the findings published in Science and discuss the details of its De Novo Protein Design Shots: NL-CVX1 (CTC-445.2d) demonstrated the ability to prevent infection of multiple human cell lines in vitro and […]Read More


Qiagen Launches Portable Digital SARS-CoV-2 Antigen Test in the US

Shots: Qiagen has initiated the commercialization of the portable digital QIAreach SARS-CoV-2 antigen test in the US that can be used by laboratories to detect active infections in 2-15mins. The test provides a higher throughput testing for SARS-CoV-2 antigen by processing up to 8 tests/ hub. The digital results do not need subjective interpretation and […]Read More